Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$106.39 USD
+0.50 (0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $106.36 -0.03 (-0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.39 USD
+0.50 (0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $106.36 -0.03 (-0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy
by Zacks Equity Research
CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.
Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.
Cigna (CI) Unit Unveils Pricing Model for Pharmacy Clients
by Zacks Equity Research
Cigna's (CI) sub-unit Express Scripts introduces a pricing option for prescription drugs that may bolster the customer base and fetch higher pharmacy revenues to the health insurer.
Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates
by Zacks Equity Research
Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.
Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate
by Zacks Equity Research
The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) subcutaneous (SC) formulation of immuno-oncology drug Tecentriq gets CHMP's positive recommendation for all approved indications.
Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition
by Zacks Equity Research
Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Humana's (HUM) CenterWell Unit Plans Expansion in Indiana
by Zacks Equity Research
Humana's (HUM) CenterWell brand will open four senior-focused primary care centers across Indianapolis in order to address the unique needs of the area's senior population.
LGND or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study
by Zacks Equity Research
Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
by Zacks Equity Research
The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly Results
by Shaun Pruitt
After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.
Ligand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
by Zacks Equity Research
Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
by Zacks Equity Research
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
by Zacks Equity Research
Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.
Compared to Estimates, Ligand (LGND) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Ligand (LGND) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip
by Zacks Equity Research
Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.
Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.
bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
by Zacks Equity Research
bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.